New Stock News | Zaiying Pharmaceutical (688266.SH) has submitted its application to the Hong Kong Stock Exchange again.

According to the Hong Kong Stock Exchange's disclosure on August 12, Suzhou Zejing Biotechnology Co., Ltd. (hereinafter referred to as Zejing Pharmaceutical (688266.SH)) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC as the sole sponsor. The company previously submitted an application to the Hong Kong Stock Exchange on December 19, 2025. The prospectus shows that Zejing Pharmaceutical is a comprehensive biopharmaceutical company focused on the discovery, research and development, and commercialization of innovative small molecules and biologics, with a strategic focus on oncology, autoimmune diseases, and hemostasis/blood disorders. As of the latest feasible date, the company has four marketed drugs: Zepu Sheng (Tolvaptan and Dexamethasone Tablets), which is Chinas first locally developed multi-target small molecule drug for first-line treatment of advanced liver cancer; Zepu Ping (JAK Inhibitor Tablets), which is Chinas first locally developed innovative JAK inhibitor for the treatment of myelofibrosis; Zepu Ning (Recombinant Human Thrombin), which is the only recombinant human thrombin developed using recombinant DNA technology and successfully commercialized in China; and Ze Su Ning (Injectable Human Thyroid-Stimulating Hormone Beta), which is the only recombinant human thyroid-stimulating hormone approved in China for diagnostic use in postoperative follow-up of patients with differentiated thyroid cancer, for radioactive iodine whole body imaging and serum thyroglobulin monitoring.